Allison R Kirkpatrick1, Eshan U Patel1, Connie L Celum2, Richard D Moore3, Joel N Blankson3, Shruti H Mehta4, Gregory D Kirk4, Joseph B Margolick5, Thomas C Quinn1,3, Susan H Eshleman6, Oliver Laeyendecker1,3. 1. 1 Laboratory of Immunoregulation, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Baltimore, Maryland. 2. 2 Department of Medicine, University of Washington , Seattle, Washington. 3. 3 Department of Medicine, Johns Hopkins University School of Medicine , Baltimore, Maryland. 4. 4 Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health , Baltimore, Maryland. 5. 5 Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health , Baltimore, Maryland. 6. 6 Department of Pathology, Johns Hopkins University School of Medicine , Baltimore, Maryland.
Abstract
BACKGROUND: Accurate methods for cross-sectional incidence estimation are needed for HIV surveillance and prevention research. We developed an avidity assay based on the fourth-generation Genetic Systems HIV Combo Ag/Ab EIA (Bio-Rad Combo assay) and evaluated its performance. MATERIALS AND METHODS: The Bio-Rad Combo assay was modified incubating samples with and without 0.025 M diethylamine (DEA). The avidity index (AI) was calculated as the ratio of the DEA-treated to untreated result for a specific sample. We analyzed 2,140 samples from 808 individuals from the United States with known duration of HIV infection. The mean duration of recent infection (MDRI) and the false-recent rate (FRR, fraction of samples from individuals known to be infected >2 years misclassified as recent) were calculated for AI cutoffs of 20%-90% for the avidity assay alone and in combination with a viral load assay (VL, limit of detection 400 copies/ml). Factors associated with misclassification of samples collected ≥2 years after infections were also evaluated. RESULTS: The MDRI for the Bio-Rad Combo Avidity assay ranged from 50 days using an AI cutoff of 20% to 276 days using an AI cutoff of 90%; the FRR ranged from 0% to 9%. When samples with a VL <400 copies/ml were classified as nonrecent, the FRRs were reduced approximately twofold and the MDRI estimates were reduced by ∼20%. An AI cutoff of 50% provided an MDRI of 135 days with an FRR of 2.1%. All samples from elite suppressors had an AI >80%. In adjusted analysis, viral suppression and low CD4 cell count were significantly associated with misclassification among individuals infected >2 years. CONCLUSIONS: This modified Bio-Rad Combo Avidity assay may be a useful tool for cross-sectional HIV incidence estimation. Further research is needed to evaluate use of this assay in combination with other assays to accurately estimate population-level HIV incidence.
BACKGROUND: Accurate methods for cross-sectional incidence estimation are needed for HIV surveillance and prevention research. We developed an avidity assay based on the fourth-generation Genetic Systems HIV Combo Ag/Ab EIA (Bio-Rad Combo assay) and evaluated its performance. MATERIALS AND METHODS: The Bio-Rad Combo assay was modified incubating samples with and without 0.025 M diethylamine (DEA). The avidity index (AI) was calculated as the ratio of the DEA-treated to untreated result for a specific sample. We analyzed 2,140 samples from 808 individuals from the United States with known duration of HIV infection. The mean duration of recent infection (MDRI) and the false-recent rate (FRR, fraction of samples from individuals known to be infected >2 years misclassified as recent) were calculated for AI cutoffs of 20%-90% for the avidity assay alone and in combination with a viral load assay (VL, limit of detection 400 copies/ml). Factors associated with misclassification of samples collected ≥2 years after infections were also evaluated. RESULTS: The MDRI for the Bio-Rad Combo Avidity assay ranged from 50 days using an AI cutoff of 20% to 276 days using an AI cutoff of 90%; the FRR ranged from 0% to 9%. When samples with a VL <400 copies/ml were classified as nonrecent, the FRRs were reduced approximately twofold and the MDRI estimates were reduced by ∼20%. An AI cutoff of 50% provided an MDRI of 135 days with an FRR of 2.1%. All samples from elite suppressors had an AI >80%. In adjusted analysis, viral suppression and low CD4 cell count were significantly associated with misclassification among individuals infected >2 years. CONCLUSIONS: This modified Bio-Rad Combo Avidity assay may be a useful tool for cross-sectional HIV incidence estimation. Further research is needed to evaluate use of this assay in combination with other assays to accurately estimate population-level HIV incidence.
Authors: Andrew F Longosz; David Serwadda; Fred Nalugoda; Godfrey Kigozi; Veronica Franco; Ronald H Gray; Thomas C Quinn; Susan H Eshleman; Oliver Laeyendecker Journal: AIDS Res Hum Retroviruses Date: 2013-10-25 Impact factor: 2.205
Authors: C L Celum; S P Buchbinder; D Donnell; J M Douglas ; K Mayer; B Koblin; M Marmor; S Bozeman; R M Grant; J Flores; H W Sheppard Journal: J Infect Dis Date: 2000-12-08 Impact factor: 5.226
Authors: Jens D Lundgren; Abdel G Babiker; Fred Gordin; Sean Emery; Birgit Grund; Shweta Sharma; Anchalee Avihingsanon; David A Cooper; Gerd Fätkenheuer; Josep M Llibre; Jean-Michel Molina; Paula Munderi; Mauro Schechter; Robin Wood; Karin L Klingman; Simon Collins; H Clifford Lane; Andrew N Phillips; James D Neaton Journal: N Engl J Med Date: 2015-07-20 Impact factor: 91.245
Authors: Oliver Laeyendecker; Ron Brookmeyer; Matthew M Cousins; Caroline E Mullis; Jacob Konikoff; Deborah Donnell; Connie Celum; Susan P Buchbinder; George R Seage; Gregory D Kirk; Shruti H Mehta; Jacquie Astemborski; Lisa P Jacobson; Joseph B Margolick; Joelle Brown; Thomas C Quinn; Susan H Eshleman Journal: J Infect Dis Date: 2012-11-05 Impact factor: 5.226
Authors: Yen T Duong; Maofeng Qiu; Anindya K De; Keisha Jackson; Trudy Dobbs; Andrea A Kim; John N Nkengasong; Bharat S Parekh Journal: PLoS One Date: 2012-03-27 Impact factor: 3.240
Authors: Sung Yong Park; Tanzy M T Love; Lucy Reynell; Carl Yu; Tina Manzhu Kang; Kathryn Anastos; Jack DeHovitz; Chenglong Liu; Kord M Kober; Mardge Cohen; Wendy J Mack; Ha Youn Lee Journal: Sci Rep Date: 2017-08-07 Impact factor: 4.379
Authors: Shelley N Facente; Eduard Grebe; Andrew D Maher; Douglas Fox; Susan Scheer; Mary Mahy; Shona Dalal; David Lowrance; Kimberly Marsh Journal: JMIR Public Health Surveill Date: 2022-03-11